Top Markets
Coin of the day
IDL Diagnostics AB (publ) IDL Diagnostics AB (publ)

IDL Diagnostics AB (publ)

IDLDX
Rank in Stocks #32452
Specializing in in vitro diagnostics (IVD), IDL Diagnostics AB (publ) develops... Specializing in in vitro diagnostics (IVD), IDL Diagnostics AB (publ) develops and markets diagnostic tests aimed at detecting cancer and bacterial infections within the Swedish market. Its product portfolio includes UBC Rapid, a point-of-care solution for both diagnosing and tracking bladder cancer; AroCell TK 210 ELISA, utilized as a biomarker for identifying tumor cells; and TUBEX TF, an in vitro diagnostic tool for pinpointing acute typhoid fever. Formerly operating as AroCell AB (publ), the company is scheduled to adopt the name IDL Diagnostics AB (publ) in May 2025. Established in 2000, its operations are headquartered in Stockholm, Sweden.
Share Price
$0.04367217
Last synced: 2026-08-17
Market Cap
$10.06M
Change (1 day)
3.99%
Change (1 year)
-26.77%
Country
SE
Trade IDL Diagnostics AB (publ) (IDLDX)

Category

P/E ratio for IDL Diagnostics AB (publ) (IDLDX)
P/E ratio as of 2026 TTM: 0
According to IDL Diagnostics AB (publ) latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for IDL Diagnostics AB (publ) from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
31.59 -
US
35.83 -
US
- -
CN
-227.89 -
US
38.69 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.